Repository logo
 

Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia.

Published version
Peer-reviewed

Change log

Abstract

Recent studies have reported early cerebellar and subcortical impact in the disease progression of genetic frontotemporal dementia (FTD) due to microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72). However, the cerebello-subcortical circuitry in FTD has been understudied despite its essential role in cognition and behaviors related to FTD symptomatology. The present study aims to investigate the association between cerebellar and subcortical atrophy, and neuropsychiatric symptoms across genetic mutations. Our study included 983 participants from the Genetic Frontotemporal dementia Initiative including mutation carriers and noncarrier first-degree relatives of known symptomatic carriers. Voxel-wise analysis of the thalamus, striatum, globus pallidus, amygdala, and the cerebellum was performed, and partial least squares analyses (PLS) were used to link morphometry and behavior. In presymptomatic C9orf72 expansion carriers, thalamic atrophy was found compared to noncarriers, suggesting the importance of this structure in FTD prodromes. PLS analyses demonstrated that the cerebello-subcortical circuitry is related to neuropsychiatric symptoms, with significant overlap in brain/behavior patterns, but also specificity for each genetic mutation group. The largest differences were in the cerebellar atrophy (larger extent in C9orf72 expansion group) and more prominent amygdalar volume reduction in the MAPT group. Brain scores in the C9orf72 expansion carriers and MAPT carriers demonstrated covariation patterns concordant with atrophy patterns detectable up to 20 years before expected symptom onset. Overall, these results demonstrated the important role of the subcortical structures in genetic FTD symptom expression, particularly the cerebellum in C9orf72 and the amygdala in MAPT carriers.

Description

Funder: Alzheimer Society of Canada; Id: http://dx.doi.org/10.13039/501100000143


Funder: Weston Brain Institute; Id: http://dx.doi.org/10.13039/100012479


Funder: Fonds de Recherche du Québec ‐ Santé


Funder: Canadian Institutes of Health Research; Id: http://dx.doi.org/10.13039/501100000024


Funder: NIHR Rare Diseases Translational Research Collaboration


Funder: Deutsche Forschungsgemeinschaft; Id: http://dx.doi.org/10.13039/501100001659

Journal Title

Hum Brain Mapp

Conference Name

Journal ISSN

1065-9471
1097-0193

Volume Title

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Sponsorship
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Medical Research Council (MC_U105597119)
Medical Research Council (MC_UU_00005/12)

Relationships

Is derived from: